Polaris Capital Management said the following ... switching patients to Skyrizi or Rinvoq rather than Humira biosimilars.” Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company ...

Polaris Capital Management said the following ... that could enable monthly or better dosing for MariTide.” Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company that discovers ...

Existing backers also bought in, including Bristol Myers Squibb, Eli Lilly, Pfizer Ventures, Novartis Venture Fund, Leaps by Bayer, Alexandria Venture Investments, Polaris Partners, and Vida Ventures.

This was the stock's second consecutive day of losses.

William Blair upped their Q2 2025 earnings estimates for Bristol-Myers Squibb in a note issued to investors on Tuesday, March ...

Bristol Myers Squibb Co. closed 6.82% below its 52-week high of $63.33, which the company reached on March 11th.

Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last ...

Bristol Myers Squibb (BMY) closed the most recent trading day at $60.18, moving +0.6% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.78%.

PRINCETON, N.J., March 03, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62 ...

Bullish option flow detected in Bristol Myers ( BMY) Squibb with 17,811 calls trading, 1.1x expected, and implied vol increasing over 2 points to 28.33%. May-25 60 calls and 3/14 weekly 63 calls are ...

Bristol-Myers Squibb has shown exceptional success in addressing challenges directly related to the introduction of generic versions of Revlimid and Sprycel. So, the gem in its oncology franchise ...

Bristol Myers Squibb stock (NYSE: BMY) has gained 7% this year, outperforming the S&P 500 which has declined 1%. BMS’s strong Q4 performance has helped drive its positive momentum. While markets ...